Reuters logo
BRIEF-AstraZeneca's MedImmune, NGM Biopharmaceuticals in deal to develop therapies for diabetes and obesity
June 17, 2013 / 7:21 AM / 4 years ago

BRIEF-AstraZeneca's MedImmune, NGM Biopharmaceuticals in deal to develop therapies for diabetes and obesity

LONDON, June 17 (Reuters) - AstraZeneca PLC : * Medimmune,NGM Biopharmaceuticals announce agreement to discover and develop

therapies for diabetes and obesity * MedImmune,NGM will jointly advance peptide and antibody drug candidates based

on discovered eec hormones * MedImmune will be responsible for global development,

manufacture,commercialisation of compounds from collaboration

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below